Lucid Diagnostics (LUCD) EBIT Growth (3y) (2023 - 2026)

Lucid Diagnostics (LUCD) EBIT Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -3.76%
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 8.39%
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 6.17%
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 25.88%
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 7.13%
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 75.54%
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 34.83%
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -2.70%
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Lucid Diagnostics 133.09 Mn 105.22 Mn -325,000.00 5.42%

Historic Data

Download Data
DateValue
Mar 31, 2026 5.42%
Dec 31, 2025 2.19%
Sep 30, 2025 6.48%
Jun 30, 2025 8.02%
Mar 31, 2025 -0.58%
Dec 31, 2024 -3.26%
Sep 30, 2024 -21.56%
Jun 30, 2024 -22.99%
Mar 31, 2024 -43.49%
Dec 31, 2023 -61.26%
Sep 30, 2023 -76.56%